Cargando…

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials

BACKGROUND: The immunogenicity profile of the 9-valent HPV (9vHPV) vaccine was evaluated across five phase III clinical studies conducted in girls and boys 9–15 years of age and young women 16–26 years of age. The effect of baseline characteristics of subjects on vaccine-induced HPV antibody respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Lone K., Restrepo, Jaime, Moreira, Edson D., Iversen, Ole-Erik, Pitisuttithum, Punnee, Van Damme, Pierre, Joura, Elmar A., Olsson, Sven-Erik, Ferris, Daron, Block, Stan, Giuliano, Anna R., Bosch, Xavier, Pils, Sophie, Cuzick, Jack, Garland, Suzanne M., Huh, Warner, Kjaer, Susanne K., Bautista, Oliver M., Hyatt, Donna, Maansson, Roger, Moeller, Erin, Qi, Hong, Roberts, Christine, Luxembourg, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883201/ https://www.ncbi.nlm.nih.gov/pubmed/28720442 http://dx.doi.org/10.1016/j.pvr.2017.03.002

Ejemplares similares

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
por: Olsson, Sven-Eric, et al.
Publicado: (2020)

Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
por: Ferris, Daron G., et al.
Publicado: (2020)

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region()
por: Castellsagué, Xavier, et al.
Publicado: (2016)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Decreased Ovarian Reserve Predicts Inexplicability of Recurrent Miscarriage? A Retrospective Analysis
por: Pils, Sophie, et al.
Publicado: (2016)

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
por: Joura, Elmar A, et al.
Publicado: (2012)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
por: Kjaer, Susanne K., et al.
Publicado: (2020)

HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017)

The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
por: Gensthaler, Lisa, et al.
Publicado: (2020)

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2019)

Vaccine development lessons between HIV and COVID-19
por: Vasan, Sandhya, et al.
Publicado: (2021)

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
por: Kamolratanakul, Supitcha, et al.
Publicado: (2021)

What do women with gynecologic cancer know about HPV and their individual disease? A pilot study
por: Pils, Sophie, et al.
Publicado: (2014)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Rate of Involved Endocervical Margins According to High-Risk Human Papillomavirus Subtype and Transformation Zone Type in Specimens with Cone Length ≤ 10 mm versus > 10 mm—A Retrospective Analysis
por: Paternostro, Chiara, et al.
Publicado: (2023)

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
por: Brown, Darron R., et al.
Publicado: (2022)

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
por: Garland, S M, et al.
Publicado: (2018)

HPV screening in the urine of transpeople - A prevalence study
por: Pils, Sophie, et al.
Publicado: (2022)

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women()
por: Ruiz-Sternberg, Ángela María, et al.
Publicado: (2017)

Evaluating the Impact of the Covariance of the Friction and Potential Gradient on Describing the Infiltration Process
por: van Damme, Myron
Publicado: (2018)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023)

Pregnancy Outcomes Among HIV-Infected Women Undergoing Antiretroviral Therapy
por: Areechokchai, Darin, et al.
Publicado: (2009)

Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adults
por: Worasathit, Rawipun, et al.
Publicado: (2015)

Antimicrobial Stewardship in Tropical Infectious Diseases: Focusing on Dengue and Malaria
por: Siribhadra, Ashley, et al.
Publicado: (2022)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
por: Petry, Karl-Ulrich, et al.
Publicado: (2018)

On the Automaticity of the Evaluative Priming Effect in the Valent/Non-Valent Categorization Task
por: Spruyt, Adriaan, et al.
Publicado: (2015)

Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand
por: Osman, Mayada, et al.
Publicado: (2021)

Adherence and Health Problems in Thai Travellers Living with HIV
por: Madsalae, Krit, et al.
Publicado: (2022)

Atlantic multi-decadal oscillation covaries with Agulhas leakage
por: Biastoch, Arne, et al.
Publicado: (2015)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
por: Thiem, Vu Dinh, et al.
Publicado: (2021)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

Clinical Factors for Severity of Plasmodium falciparum Malaria in Hospitalized Adults in Thailand
por: Sagaki, Patrick, et al.
Publicado: (2013)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

The Covariate's Dilemma
por: Mefford, Joel, et al.
Publicado: (2012)

Assessment of gene-covariate interactions by incorporating covariates into association mapping
por: Chiu, Yen-Feng, et al.
Publicado: (2009)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Knowledge, attitude, and practices toward COVID-19 among the international travelers in Thailand
por: Prapaso, Suttiporn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e3r16p0cdajp5scmn2hedpip2j